In our ongoing study focused on Corydalis cava (Fumariaceae), used in folk medicine in the treatment of memory dysfunctions, we have investigated fifteen previously isolated alkaloids for their potential multifunctional activity on Alzheimer's disease (AD) targets. Determination of ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibition was carried out using a BACE1-Immobilized Enzyme Reactor (IMER) by validating the assay with a multi-well plate format Fluorescence Resonance Energy Transfer (FRET) assay. Seven alkaloids out of fifteen were found to be active, with (-)-corycavamine (3) and (+)-corynoline (5) demonstrating the highest BACE1 inhibition activity, in the micromolar range, in a concentration dependent manner. BACE1-IMER was found to be a valid device for the fast screening of inhibitors and the determination of their potency. In a permeation assay (PAMPA) for the prediction of blood-brain barrier (BBB) penetration, the most active compounds, (-)-corycavamine (3) and (+)-corynoline (5), were found to be able to cross the BBB. Not all compounds showed activity against glycogen synthase kinase-3β (GSK-3β) and casein kinase-1 (CK-1). On the basis of the reported results, we found that some Corydalis cava alkaloids have multifunctional activity against AD targets (prolyl oligopeptidase, cholinesterases and BACE1). Moreover, we tried to elucidate the treatment effectivity (rational use) of its extract in memory dysfunction in folk medicine.
Introduction
Alzheimerʼs disease (AD) is a neurodegenerative progressive disorder and the most common form of dementia amongst the elderly. AD is characterized by pathological hallmarks: selective cholinergic neuronal loss, intracellular neurofibrillary tangles (NFTs) composed of abnormally intracellular phosphorylated τ-protein, and extracellular senile plaques (SPs) [1] .
SPs are deposits of β-amyloid peptide (Aβ) which originate in abnormal processing of amyloid precursor protein (APP) [2] . Aβ production from APP depends on activities of the enzymes -secretase, β-secretase (BACE1) and γ-secretase. However, during the nonamyloidogenic pathway -secretase cleaves APP at a site within the Aβ domain, thus precluding Aβ formation. Within the amyloidogenic pathway, the proteolytic sequential action of BACE1 and γ-secretase lead to the production of neurotoxic Aβ peptides from APP [3, 4] . Thus, inhibitors of BACE1 and γ-secretase represent possible therapeutic hits for nonsymptomatic AD treatment. Although γ-secretase inhibitors triggered toxic effects in human trials, in the case of γ-secretase knockout mice the effect was lethal at their embryonic stage; this enzyme has various physiological functions and it is essential for normal development [5] . On the other hand, BACE1 inhibition decreased Aβ production, and BACE1 knockout in mice terminated Aβ40 and Aβ42 production without any severe dysfunction [6] . Therefore, BACE1 inhibition has become a promising approach for AD treatment. One of the neuropathological characteristics of AD is the presence of neurofibrillary tangles (NFTs) consisting of paired helical filaments, with the main component being hyperphosphorylated τ-protein [7] . Phosphorylation of τ-proteins is primarily dependent on GSK-3β and cyclin-dependent kinase 5 (CDK5) [8] . represents the isoform of GSK-3. This enzyme is involved in glycogen synthesis, but more recently, GSK-3 has been found to play an important role in the central nervous system (CNS) [9, 10] . When the enzyme is dysregulated, GSK-3 proves to be a pathogenic molecule in tissues -in the CNS the enzyme is associated with neurodegenerative disorders, stroke and mood disorders [11] . Specifically in AD patient brains, abnormally high GSK-3 activity is linked with τ-hyperphosphorylation, as mentioned above, but also with memory impairment, increased Aβ production and local plaque-associated microglial-mediated inflammatory responses [12] . Moreover, casein kinase-1 (CK-1) belongs to the kinases responsible for τ-hyperphosphorylation as well. The CK-1 activity is stimulated by Aβ and the enzyme is involved in the regulation of Aβ production in neurons [13] . Thus, CK-1 and GSK-3β inhibitors offer another valuable approach toward AD therapies.
Given the complexity and the interconnected pathological pathways of the disease, lately multi-target drug approaches have been carried out to provide a more effective treatment for AD. A multi-target directed ligand is able to modulate simultaneously more than one neurogenerative pathway, for example amyloid formation and cognitive functions, when more than one activity is shown by the same molecule. Another potential therapeutic approach consists of combining active molecules, each one hitting one specific target. These strategies have explored inhibitors acting on different sites of the acetylcholinesterase enzyme, producing at least two different activities for multi-target drugs acting on different AD targets [14] [15] [16] [17] [18] [19] .
In previous studies, several species of Corydalis have been reported to be used in folk medicine for treating memory dysfunction [20, 21] . Tubers of C. cava are a rich source of isoquinoline alkaloids of different structural types [22] [23] [24] [25] [26] . In our previous study focused on tertiary alkaloids from Corydalis cava (L.) Schweigg. et Koerte (Fumariaceae), some potent inhibitors of human cholinesterases were found [26] . In the current study we decided (14) , and (+)-N-methyllaurotetanine (15) trigger inhibition effects which could be valuable or useful for the potential prevention of nonsymptomatic AD. Therefore, their potential inhibition effects on BACE1, GSK-3β and CK-1 were evaluated. BACE1 inhibition by natural products has become interesting for finding potential drugs with anti-AD effects. Several potent BACE1 inhibitors have been discovered, mainly among nonalkaloidal compounds, but recent studies have confirmed BACE1 inhibition activity of alkaloids as well [3, [27] [28] [29] [30] . Similarly, GSK-3β and CK-1 have become promising targets for AD treatment [31, 32] . A review by Martinez et al. reported that several potent inhibitors of GSK-3β have been discovered from marine organisms [31] . Moreover, compounds derived from natural sources are often endowed with unique and original scaffolds, which are very promising in terms of new chemical structures to be explored in relation to multi-target activities [14] .
The most common methods used for determination of BACE1 inhibition activities of compounds involve fluorimetric assays in multi-well plates based on the FRET principle.
FRET assays are sensitive and homogenous, but have several basic drawbacks such as high enzyme consumption, long analysis times, variability in the different sources and concentration of enzymes, and impossibility of re-usability of the used enzyme, as well as complex robotic liquid handling. Furthermore, many compounds can produce false positive or negative results due to their limitations with solubility under FRET assay conditions, which lead to production of aggregates or due to interference with substrate hydrolysis products, because some compounds can possess fluorescent aromatic and/or heterocyclic moieties in their structures [33] . On the other hand, the use of immobilized enzymatic systems has proved a valid alternative to solution enzymatic assays, showing the advantages of speed, automation and reusability of the immobilized enzyme reactor [33] [34] [35] .
Finally, if compounds have to be considered as drug candidates for AD treatment, it is necessary to determine their ability to cross the blood-brain barrier (BBB), which is a necessary feature of all potential substances for the treatment of CNS-related disorders. The BBB is a protective system that prevents substances and molecules from the blood from entering into the brain. Molecules which are soluble in lipids are able to penetrate relatively easily through the BBB via lipid cell membranes. On the other hand, hydrophilic molecules cross the barrier by use of specialized carrier-mediated transport mechanisms only [36] . The parallel artificial membrane permeability assay (PAMPA) is a model assay for determination of penetration via the BBB. The PAMPA is a high throughput method developed for prediction of passive permeability through biological membranes, employing a brain lipid porcine membrane [37] .
Based on these all considerations, we aimed to disclose any multi-target activity of the alkaloids of C. cava by determination of their potential inhibition effects on BACE1, GSK-3β and CK-1, and obtained results from this study to combine together with their previously determined anti-AD activities (inhibition of prolyl oligopeptidase and human cholinesterases).
We used an on-line HPLC system for BACE1 characterization of C. cava alkaloids by validation through FRET assay. The most active alkaloids in this study were tested in the permeation assay for the prediction of BBB passive penetration ability to explicate the putative treatment effectivity (rational use) of its extract in memory dysfunction in folk medicine.
Results and discussion
In order to validate a HPLC system, FRET assays using a human recombinant BACE1 (hrBACE1) in multi-wells in "solution studies" were also carried out. Compounds 1, 9, 10, and 15 gave raise to fluorescent interference with the substrate hydrolysis product of M-2420.
For these compounds the substrate M-2420 could not be used, and, therefore, they were screened with the fluorogenic Panvera peptide (Rhodamine-Glu-Val-Asn-Leu-Asp-Ala-GluPhe-Lys-quencher) at higher excitation and emission wavelengths (λ exc = 544 nm, λ em = 590 nm). The results of inhibition studies are reported in Table 1 . Firstly, all compounds were screened at 5 µM for their ability to inhibit hrBACE1 by both the on-line HPLC assay and in solution FRET assay. inhibition (quaternary alkaloid magnoflorine showed an IC 50 value > 100 µM). An analogous absence of activity towards BACE1 was found for protoberberine alkaloids 1, 2, 4, and 12, with the missing methylenedioxy-group in the D ring, and aporphine alkaloids 9, 10, and 15 in our series of compounds. Interestingly, most C. cava alkaloids with BACE1 inhibition activity also possess the methylenedioxy-group, despite the group including different structural types of isoquinoline alkaloids (3, 6, and 8 are protopines, 5 is a benzophenanthridine alkaloid, and 7 is classified as a secoberberine alkaloid). In the case of the protopine alkaloids 3, 6, and 8 it seems that the methylenedioxy-group in 3 is responsible/necessary for BACE1 inhibition activity in a dose-dependent manner.
Even if there are differences in IC 50 values of inhibitors tested in FRET and IMER assays the different IC 50 values can be caused due to different conditions used in both methods (e.g.
for the on-line method 30 times higher concentrated samples than that used in solution method are required, furthermore, a different contact time -an incubation time of around an hour is required for FRET assay while for on-line method the inhibitor is flushed on IMER surface at a specific flow rate for less than a minute). However, IMER methodology has been demonstrated to give the opportunity of obtain well correlated results to those obtained by in solution assays [34, 35] . Moreover, the pIC 50 values from on-and off-line studies is a key requisite in order to compare data from on-line studies with data from in solution assay [38, 39] . This was well demonstrated for BACE1 known inhibitors with inhibitor activity ranging from the low nanomolar range to the high micromolar range [34] . Compounds 1−15 were also evaluated for their GSK-3β and CK-1 inhibition activities. First, the alkaloids were screened at 10 µM in both kinase assays. The alkaloids were considered as inactive (percentage inhibition was < 10 % in both cases) with respect to the known inhibitors of GSK-3β and CK-1 {alsterpaullone (IC 50 = 5.03 ± 0.12 nM) and IC261 (IC 50 = 1.00 µM)} [43] [44] .
The BACE1 inhibitors 3 and 5 were evaluated for their ability to cross the BBB. In order to explore the capability of the tested compounds to penetrate into the brain, the PAMPA-BBB method described by Di et al. was used [37] . The in vitro permeability (Pe) of 9 commercial drugs through the lipid membrane extract, together with 3 and 5, were determined; the results are presented in Table 2 . An assay validation has been previously performed comparing the reported permeability values of commercial drugs with the experimental data obtained by this method. Based on data obtained for good correlation between the experimentally described values, it was possible to classify compounds as CNS+ when they presented a permeability > 3.88×10 -6 cm s -1 [45] . Therefore we can consider that alkaloids 3 and 5 are able to cross the BBB by passive permeation. Although some compounds in this study showed BACE1 inhibition activity only (considered inactive against GSK-3β and CK-1), C. cava alkaloids also possess multi-targeting activities for potential prevention and treatment of AD, similar to Coptidis Rhizoma alkaloids influencing both amyloid formation and cognitive functions by BACE1, cholinesterase inhibition and antioxidant activities [29] . In addition to the BACE1 inhibition activity mentioned above, alkaloids from C. cava had previously demonstrated anticholinesterase activities towards human AChE, BuChE and prolyl oligopeptidase [26, 46] . Briefly, tertiary protoberberine alkaloids of C. cava principally inhibited AChE, in particular 1 and 2. BuChE was inhibited mainly by the aporphine and protopine alkaloids 10 and 6, respectively [26] .
In comparison, Coptidis Rhizoma quaternary protoberberine alkaloids exerted very potent balanced inhibition of AChE and BuChE activities with low micromolar IC 50 values [29] .
Their significant anticholinesterase activity is associated with planarity, substitutions on the molecule, positive charge and aromaticity of the nitrogen [47] . However, quaternary alkaloids might have problems with crossing the BBB [48] . Compounds 1, 5 and 12 were found to be prolyl oligopeptidase (POP) inhibitors, the activities of which were comparable with the standard, berberine, but these alkaloids are not so potent POP inhibitors as known inhibitors (e.g. Z-prolyl-prolinal) [46] .
If we summarize the alkaloids of C. cava that can influence two or more targets (BACE1, cholinesterases and prolyl oligopeptidase; Table 3 ), the most active compounds are 1, 3, 5, 6, 7, 8, and 11, shown in Figure 1 . those data in literature [22, 49] . We determined the content of compounds 4 and 10 in the airdried plant material as 1.25 ± 0.12 % and 2.81 ± 0.27 %, respectively. Neuroprotective activity of 4 and 10 was found to be low or mild in this study and as it was published by us previously [26, 46] . Interestingly, Adsersen et al. published that compounds 9 and 10 exerted cholinesterase inhibitory activity against nonhuman cholinesterases (10: IC 50 AChE = 40 ± 2 µM and IC 50 BChE = 83 ± 2 µM) [50] . In our previous study the alkaloid 9 showed mild anticholinesterase activity on human AChE (IC 50 AChE = 208.0 ± 6.8 µM) [26] . The HPLC determination showed that 9 was the third major alkaloid in the extract (1.02 ± 0.10 %). Based on the HPLC analysis, other isolated C. cava alkaloids represent minor alkaloids, the content for each compound was < 0.57 % in the dried material. It follows that their contribution to neuroprotective activity of C. cava tuber extracts is mild. Therefore, the treatment effectivity by C. cava extracts in memory dysfunction in folk medicine is not corroborated by alkaloids inhibition potency due to their quantitative content.
Conclusions
Fifteen alkaloids previously isolated from Corydalis cava (Fumariaceae) were evaluated for their multi-target activity on BACE1, GSK-3β and CK-1. BACE1 inhibition activity was 
Material and methods

Materials and apparatus
BACE1 FRET assays were carried out using a Fluoreskan Ascent spectrofluorometer (beam were measured on a UV/VIS Lambda Bio 20 spectrometer (Perkin Elmer, Massachusetts, USA) and a Jasco FP-6200 spectrofluorometer (Jasco, Cremella, Italy), respectively.
HrBACE1-IMER was prepared and characterized as previously reported [34] . The IMER was inserted into the HPLC system consisting of a Jasco PU-1580 solvent delivery system 
Corydalis cava alkaloids
The detailed procedure of extraction and isolation of 15 alkaloids from tubers of Corydalis cava has been previously described [26] . Purity of isolated compounds was ≥ 95 % (by NMR and GC).
BACE1 inhibition -FRET assay with the substrate M-2420
Inhibition studies were performed according to the following procedure [34] 
BACE1 inhibition hrBACE1-IMER assay
Inhibition studies were performed according to the following modified procedure [34] : The fluorescence detector was set at 320 nm and 420 nm for excitation and emission, respectively. 
BACE1 inhibition -FRET assay with Panvera peptide
Inhibition studies were performed according to the following procedure [35] : Stock solutions of test compounds were prepared in DMSO and then diluted in 50 mM sodium acetate buffer, Then, the fluorescent intensities were recorded at λ em = 590 nm (λ em = 545 nm). The percentage inhibition was determined in the same way as in previous BACE1 assays.
GSK-3β assay
The assay for determination of GSK-3β inhibition was performed according to the 
CK-1δ assay
The assay was performed according to the slightly modified luminescent method of Baki et al.
using Kinase-Glo reagent in assay buffer in 96-well plates [51] . The modifications involved the composition of the assay buffer, the incubation time (60 minutes) and 20 µL of assay buffer containing the substrate solution (0.1 % casein + 4 µM ATP). The assay buffer consisted of 50 mM HEPES (pH 7.5), Brij-35 (0.01 %), 10 mM MgCl 2 , 1 mM EGTA and sodium azide (0.01 %).
Parallel artificial membrane permeability assay (PAMPA)
The assay was performed according to Di et al. [35] . The validation of the assay has been described previously [45] .
